OOIR: Observatory of International Research

Papers

(The H4-Index of Respirology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong	119
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact	98
One‐year follow‐up CT findings in COVID‐19 patients: A systematic review and meta‐analysis	80
COVID‐19 infection and the broader impacts of the pandemic on healthcare workers	71
ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma	60
Current global perspectives on silicosis—Convergence of old and newly emergent hazards	55
Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*	54
Natural history and mechanisms of COPD	53
Occupational COPD—The most under‐recognized occupational lung disease?	50
Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand	46
Clusters of sleep apnoea phenotypes: A large pan‐European study from the European Sleep Apnoea Database (ESADA)	44
Air pollution and the pandemic: Long‐term PM_2.5 exposure and disease severity in COVID‐19 patients	43
Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries	41
Pathophysiology of infection with SARS‐CoV‐2—What is known and what remains a mystery	39
Treatable traits in the NOVELTY study	39
Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis	36
Predictors of lung function trajectories in population‐based studies: A systematic review	36
Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression	36
Effect of comorbid pulmonary disease on the severity of COVID‐19: A systematic review and meta‐analysis	35
Global Initiative for Asthma Strategy 2021	34
Outcomes of protracted bacterial bronchitis in children: A 5‐year prospective cohort study	34
Coagulation markers as predictors for clinical events in COPD	34
Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe	32
Lung cancer screening implementation: Complexities and priorities	30
Prevalence and burden of breathlessness in Australian adults: The National Breathlessness Survey—a cross‐sectional web‐based population survey	30

Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Austra	30
Delay or avoidance of routine, urgent and emergency medical care due to concerns about COVID‐19 in a region with low COVID‐19 prevalence: Victoria, Australia	29
Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis‐associated ILD: A randomized, open‐label trial	29
Epidemiology, clinical spectrum, viral kinetics and impact of COVID‐19 in the Asia‐Pacific region	29